A B S T R A C T Growth was evaluated in a group of 10 infants and children with familial or idiopathic classic renal tubular acidosis in whom alkali therapy was initiated at ages ranging from 8 days to 9.5 yr and administered at dosage schedules documented to sustain correction of acidosis in at least four prolonged observation periods on the Pediatric Clinical Research Ward. When alkali therapy was begun, six patients (four infants and two children) were stunted (height < 2.5 SD below mean). Of the four who were not, two infants were too young (<2 wk of age) to have becorne stunted, and two children had been docunmented earlier to be nonacidotic. At the start of alkali therapy, the heights of the patients correlated inversely with the maximal possible duration of prior acidosis.
With sustained alkali therapy: (a) each patient attained and maintained normiial stature; (b) the mean height ofthe 10 patients increased from the 1.4+±4 to the 37.0+±33 percentile (of a normal age-and sex-matched population); (c) the meani height reached the 69th percentile in the eight patienits wvhose heights could be analyzed according to parental prediction (Tanner technique) ; (d) the rate of growth inicreased two-to threefold, and normal heights were attained within 6 mo of initiating alkali therapy in the stunted infants and within 3 yr in the stunted children; (e) the height attained correlated inversely with the maximal possible duration of acidosis (before alkali therapy) only in those patients in whom alkali therapy was started after 6 mo of age, and not in those treated earlier.
The amount of alkali required to sustain correction of acidosis increased substantially during the course of treatment in each patient. The maximlal alkali requirement ranged from 4.8 to 14.1 me(l/kg per day, and in 'Abbreviation used in this paper: RTA, renal tubular acidosis.
INTRODUCTION
In infants and children with persisting classic (Type 1) renal tubular acidosis (RTA)I (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , the occurrence of stunted growth is characteristic (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) . In these patients, persisting acidosis might be critical to the causation of stunted growth (21-24, 27, 28, 31) . Ifthis is so, and if acidosis in these patients occurs only because the kidney fails to excrete acid at a rate equal to that at which nonvolative acid is presumed to be normally endogenously produced, provision of alkali therapy to these patients in amounts of 1-3 meq/kg per day should both sustain correction ofacidosis (11, 14, 19, 30, (34) (35) (36) (37) and induce correction of stunted growth, i.e., induce the occurrence of normal stature. But in the only long-term prospective study of children with clearly defined classic RTA, stunted growth apparently persisted despite provision of alkali therapy in amounts of 1-3 meq/kg per day (30) . Indeed, in some infants and children with classic RTA, in particular those whose height percentiles are less than the 3d percentile, the "pattern of growth" is said to be unaffected by alkali therapy in the amount of 2-3 meq/kg per day (19) . And in a recently described infant girl with classic RTA, the occurrence of stunted growth was not prevented by alkali therapy administered in the amount of2.5 meq/kg per day, even though this dosage was initiated on the third day of life (32) . Therefore, in children with classic RTA, either acidosis is not critical to the causation of stunted growth (33) or provision of alkali therapy in the amount of 1-3 meq/kg per day will not predictably sustain correction of acidosis (31) . In many infants with apparently classic RTA described in the older literature, several times this dosage of alkali was required to correct acidosis (2, (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) . In at least a few infants and children with clearly defined classic RTA, in whom urinary excretion of net base has been greater than 3
The Journal of Clinical Intivestigation Volumne 61 February 1978-509-527 meq/kg per day at normal (and reduced) plasma bicarbonate concentrations (renal bicarbonate wasting [15] [16] [17] ), sustained correction of acidosis has perforce required alkali therapy in amounts greater than 3 meq/kg per day (15) (16) (17) .
In the present study of 10 infants anid children with classic RTA, who were either short or frankly stunted when alkali therapy was started, we have investigated: (a) the amount of alkali therapy required to sustain correction ofacidosis; (b) the immediate and continuing effect on growth of correcting alkali therapy; and (c) the contribution of renal bicarbonate wasting to the alkali requirement.
METHODS
10 infants and children with classic RTA were studied on the Pediatric Clinical Research Ward (Table I) . Each patient had symptoms and signs characteristic of RTA (1, 2, 6, 7, 11, 22, 23) . None had hyperaminoaciduria.
In six patients, RTA occurred as an apparent Mendelian dominant trait affecting members of three (111-1) and four IV-8, IV-10, IV-l, IV-13, IV-15) successive generations oftwo unrelated kindreds (see Appendix). RTA was considered to be idiopathic in the four other patients; they are designated ID-1, ID-2, ID-3, and ID-4. Their parents and siblings had no history suggestive of RTA or hyperchloremic acidosis or evidence of impaired renal acidification, as judged from measurements of urinary pH and excretion rates of NH4+ and titratable acid. The initials of the patients' names are giveni in Table I .
Informed consent and special precautions. Both parents of each child studied were informed of the purpose, character, and risks of the studies and were specifically informed that catheterization ofthe bladder involved a small but finite risk of infection of the urinary tract. The investigators offered to assume continuing responsibility for the management of the child's illness, irrespective of whether the parents gave consent for any of the studies proposed. At the termination of each catheterization, urine collected from the catheter was cultured. During the 48 h immediately after catheterization, brisk water diuresis was maintained as a prophylaxis against urinary tract infection. Urine was again cultured 48 h after catheterization. In none ofthe patients did clinical evidence of pyelonephritis occur or urine cultures become positive.
Acid excretion during acidosis (Table I) . In all patients, spontaneous hyperchloremic acidosis was documented at the time RTA was diagnosed and therapy initiated. In all but two patients, observations of renal acid excretion were made during spontaneously occurring acidosis, either at time of diagnosis or when therapy was insufficient to prevent the occurrence of acidosis. IV-8, at ages 1 mo (48) and 12 yr, and IV-13, at age 2 wk, received oral loads of NH4Cl, 0.1 g/kg (6) .
Bicarbonate reabsorption during corrected acidosis. The relationship between plasma bicarbonate concentration and renal reabsorption and excretion of bicarbonate was examined at normal plasma bicarbonate concentrations. For at least 2 wk before each study, appropriate therapy had maintained the plasma bicarbonate concentrations at normal levels and serum potassium at 3.8 meq/liter or greater. Details of this kind of study have been described (15) .
Evaluation ofgrowth (Figs. 1 -4 ). In the Clinical Research Center, body length (infants < 18 mo, recumbent) or height (children over 18 mo, standing) was measured in triplicate at the time of diagnosis of RTA and repeated thereafter during corrective alkali therapy by at least two observers, including a research nurse and a physician. If the three measurements did not agree within 0.25 cm, they were repeated until they did. Similar measurements were also made in patient IV-13 9 mo before alkali therapy was initiated and in ID-1 5 yr before sustained corrective therapy was initiated. A number of the recorded measurements were made by referring physicians: in IV-13, 111-1, ID-3, ID-4, before their diagnosis of RTA in the Pediatric Clinical Research Center; in ID-2, IV-8, IV-l, and IV-10, after diagnosis but before alkali therapy was adjusted or initiated in the Pediatric Clinical Research Center.
Correction ofacidosis, alkali requirement (Table II) 24-h pools by methods previously described (15) .
Bicarbonate excretion after prolonged alkali therapy (Table  III) . In eight rapidly growing patients treated with alkali therapy for 11 mo to 6 yr, in whom the absolute dose of alkali therapy had not been changed for [1] [2] [3] [4] [5] [6] mo, the same absolute dose of alkali was continued under controlled metabolic conditions and the urinary excretion of net base, calcium, and other electrolytes was measured. Then, in five of the eight patients, the effect of abruptly changing the dose of alkali therapy on the urinary excretion of these substances was also investigated: In four studies, the amount of alkali therapy was abruptly reduced after correction of acidosis had been demonstrably sustained for a period of months; in one study , mild acidosis, documented to have been present for at least 1 mo, was corrected by abruptly increasing the amount of alkali therapy. Throughout each study period and for 3 days before, each patient ingested a diet of constant and known electrolyte composition. Dietary calcium intake was normal (63) . Blood samples were drawn in the morning before breakfast, at least 12 h after the last dose of bicarbonate. Blood for determination ofplasma renin was drawn between 8:00 and 9:00 a.m., when the patients had been fasting and recumbent for at least 3 h.
Inadequacy of prolonged dose of alkali therapy in excess of 4 meqlkg per day (Table IV) . In each of six children in whom the absolute dose of alkali had remained unchanged for periods ranging from 3 to 10 mo (and hence was not adjusted upward with weight gain), and in whom acidosis occurred as an outpatient, the prescribed dose of alkali was continued under controlled metabolic conditions. The acid-base status of each patient was evaluated for periods of [4] [5] [6] [7] [8] [9] [10] (26) . Tanner values for patients' height potential (predicted from mean parental height) ("after") and those for mean parental height are derived as described by Tanner (55) . Limits ofthe lightly shaded area indicate +2.5 SD from the mean; the darker area, +0.5 SD. Solid horizontal lines indicate the mean for the group; dashed horizontal lines, the median. Each oftwo unaffected parents with two progeny affected with familial RTA (IV-8 and IV-11; IV-10 and IV-13), and the parent pair of which each is a member are doubly weighted, as indicated by the horizontal dumbbell symbol (0-0). "Mean of pair" refers to the mean parental height of the mother-father pair. (B) Distributions of height percentiles (or standard deviations from normal mean height [SD]) in 10 infants and children with classic RTA, before and after alkali therapy, and in their parents. Plotted is the relationship between height percentile (or SD) and rankit, the mean normal deviate test (56) , for each affected patient before and after alkali therapy, and for their parents. A unique symbol denotes the height percentile (or SD) ofeach affected child and the mean height percentile ofthat child's parents. Rankits, also termed "ranked normal deviates," are averaged standardized scores for the highest to the lowest variate ofa group of size n, and are assigned from a table of rankits (57) . With an ideal normal distribution, all points lie on a straight line without segregation, when rankits are plotted against the ranked values of the variable on a standard arithmetic scale graph. At rankit value of 0, x = the value of the group mean: + 1 is ±SD. Circles denote affected children of family IV; the square, the affected child of family III; the diamond, ID-3; and triangles, the other children with idiopathic RTA. The four open svmbols denote the two patients from each of two age-treatment groups who were acidotic for a substantially shorter time than the other members of their age-treatment group. Of the six patients in whom alkali therapy was initiated before 6 mo of age (the early infancy agetreatment group), two (0 IV-15 and A ID-4.) were treated at <10 days of age and hence were too young to have become stunted. Of the four patients in whom alkali therapy were initiated after 6 mo of age (the older age-treatment group), two (( IV-13 and O 111-1) had been documiiented to be nonacidotic at age 2 mo and 6 i11o, respectively, 8 and 18 mo, respectively, before alkali therapy was started. Closed or partially closed symbols denote patients in whom the duration ofacidosis before alkali therapy was longer than in the other members oftheir age treatment groups: Q IV-11, A ID-1, v ID-2, and * ID-3, of the early infancy treatment group; and e IV-8 and Q IV-10 of the older treatment group, both of whom were documented to be acidotic for 3.5 and 5 vr, respectively, before corrective alkali therapy was started. The overlapping symbols indicate one set of parents with two affected children and are assigned "tie" value rankits as directed by the test (56) .
Before alkali therapy, the heights (SD) attained by the 10 patients do not lie on a straight line, but segregate into at least two clusters. Within each of the two clusters, the patients' height percentiles do lie on a straight line when assigned appropriate rankits (not shown). The mean height of the four patients whose heights make up the taller cluster, and in whom the duration of acidosis before alkali therapy was less than that ofthe other members oftheir age treatment group, was -0.95 +0.33 SD; all were small (height percentiles <30%), but none were stunted. The mean height, -2.82+±0.29 SD, of the five patients whose height percentiles make up the shorter cluster was significantly less than the mean height ofthe patients ofthe taller cluster(P < 0.001); all members of the shorter cluster were stunted. The patient with the lowest height percentile, the value of which was outside even the cluster of the shorter heights, was the member of the early infancv treatment group in whom the maximal possible duration of acidosis was longest. She had been documented to be severely acidotic at age 3 mo.
After alkali therapy, the height percentiles attained by the eight patients who could be evaluated by the Tanner technique lie on a straight line with no evidence of deviation from normal distribution. The height percentiles of the 10 patients after alkali therapy relative to the standard reference population, and those of the parents, are also normally distributed, even though both the distributions appear to be slightly perturbed by the presence of@ and e (affected children and their parents) in each group of height percentiles. In this family, the unaffected father is abnormallv small, hence in these children, height is greatly diminished (but not subnormal), presumably on that basis. The normalcy of the distribution of the height percentiles of the 10 patients after alkali therapy (as evaluated by either the standard or the Tanner technique) and before therapy was confirmed by the W statistic of Shapiro and Wilk (58) (not shown).
The rank order of the patient's individual heights before therapy' was not maintained after therapy. For six patients, the rank order of height increased; for four, it decreased. The greatest decrease in rank order occurred in ID-4, whose compliance with alkali therapy was least. The greatest increase in rank order occurred in ID-3 in whom compliance appeared complete and in whom mean parental height was greatest. ID-3 and ID-4 were alike with respect both to their ages and to the severity of their acidification defects when alkali therapy was initiated (in infancy').
(C) The height percentiles attained before and after alkali therapy as a function of the duration of acidosis preceeding the initiation ofalkali therapy, in two treatment groups: those in whom alkali therapy was started before 6 mo ofage (extreme left) and those in whom alkali therapy was initiated after 6 mo (near left and right). The height percentile (or SD) (in reference to age-and sex-matched normal populations) attained by the patient is plotted against the maximal possible duration ofacidosis before alkali therapy. (The duration between birth and initiation of alkali therapy for all patients, except IV-13 and III-1 [members of two kindreds], who were documented to have normal arterial pH and plasma bicarbonate concentration at ages 2 and 6 mo, respectively, and were not treated with alkali therapy until ages 10 mo and 2 y'r, hence, having "durations" of 8 mo and 1/2 yr, respectively.) Symbols denote individual patients, as in Fig. 1 B. ID-1 appears in both age treatment groups: in this patient, therapy was initiated at the age of4 mo (extreme left, "before" A), but metabolic acidosis continued as an outpatient (because only 10% of the dose of alkali prescribed was administered) until age 51/2 yr, when stunting was present and continuously correcting alkali therapy was initiated (near left, "before" A). The height percentiles plotted for each patient are those immediately before the initiation of alkali therapy ("before") and at the time of the last evaluation ("after") with two exceptions: The height percentiles attained by ID-1 and IV-8 after therapy are those recorded at 9 vr ofage, the oldest age permitting ofthe Tanner analysis. r values are coefficients of correlations. The regression line plotted for y as a function ofx is calculated by the method ofthe least squares.
In the patients in whom alkali therapy was initiated before 6 mo of age, a significanit inverse correlation obtained between the maximal possible duration of prior acidosis and the height percentiles attained before alkali therapy (extreme left). In these patients, who are in the early' infancy treatment group, the height attained after alkali therapy did not correlate significantly with the mlaximnal possible duration of prior acidosis (not shown: r = -0.20, standard; -0.33, Tanner). In those patients in whom alkali therapy was initiated after 6 mo ofage, and who are in the late treatment group, a significant iniverse correlation obtained between the height percentiles attained both "before" (near left) and "after" (extreme right) therapy and the maximal possible duration of prior acidosis. For the height percentiles attained after alkali therapy evaluated by standard reference population (near right), r = -0.82; 0.05 < P < 0.1. If the siame value of r obtained in a group size of six rather than of five, this correlationi would be significant (P < 0.05).
Correction of Impaired Growth in Classic Renal Tubular Acidosis Each recorded value of alkali therapy is that dosage required to sustain correction ofacidosis for an observation period ofat least 6 days.
In each patient, with the exception of ID-2, the lower value in the first interval of observation indicates the dosage of alkali therapy required initially. * Alkali therapy was administered at a dosage schedule adequate to sustain correction of acidosis from time of onset of therapy, with four exceptions: IV-15 received inadequate dosage from age 3-10 mo because of poor parental compliance and lack of follow-up; ID-4 had sporadic parental compliance with therapy; ID-1, from age 1 to 5.5 yr, received alkali therapy that was not continuously corrective, because the alkali medication received as an outpatient was 0.1 the potency prescribed; IV-8 received inadequate dosage for the first 6 yr of alkali therapy, as judged from venous CO2 contents at another hospital.
t Although the dose of alkali was not known, correction of acidosis appears to have been fairly well sustained, as judged from venous CO2 concentrations measured at another hospital.
nate concentration were measured each morning in the fasting state, before the first morning dose ofalkali. Alkali therapy was administered in an amount and dosage schedule identical with that prescribed as an outpatient. Blood for determination of plasma renin was drawn between 8:00 and 9:00 a.m., when the patients had been fasting and recumbent for 3 h. Urine was collected in 24-h pools by methods described previously (15) . Laboratory methods. Laboratory determinations were carried out as described previously (8, 10) .
RESULTS
Physiological classification of RTA Acid excretion during acidosis (Table I ). In each of 10 patients, urinary pH was inappropriately high during moderate as well as severe acidosis; excretion rates of urinary ammonium and titratable acid during acidosis were subnormal except for the initially observed excretion rates of ammonium in III-1 and ID-3. During acidosis, in patients ID-3, ID-4, and IV-11, the rate of urinary excretion of bicarbonate exceeded the sum of the rates of titratable acid and ammonium, i.e., net base excretion occurred. IV-13 at age 2 wk did not have spontaneously occurring acidosis, although her response to NH4Cl-induced acidosis was abnormal. In all patients, the impairment in renal acidification had persisted. In all patients, glomerular filtration rate (inulin clearance) has remained normal.
Bicarbonate studies. In each of the 10 patients, the general relationship between plasma bicarbonate concentration and the renal reabsorption and excretion of bicarbonate was similar to that previously described in children and adults with classic RTA (4, 5, 9, 10, 15). Growth before corrective alkali therapy (Figs. 1 -4) GROUP Standard reference population analysis (Fig.  1) . The mean height of the 10 patients before adequate alkali therapy was initiated was in the 1.4th percentile (±4) of a normal population matched for age and sex. Four patients were not stunted (mean height -0.95±0.33 SD); of these, two were too young for stunting to have occurred and two were documented at 2 and 6 mo of age to be nonacidotic, 8 and 18 mo before alkali therapy was started (Fig. lb) . Six patients were stunted; their mean height was -3.4±1.1 SD.
Tanner analysis (Fig. 1) . Analysis of growth by the Tanner technique requires that the ages of the children be between 2 and 9 yr. Since 7 of the 10 children were first diagnosed and treated in infancy, their heights before therapy could not be evaluated by the Tanner technique. For three children first diagnosed and treated in childhood and one child (ID-1) inadequately treated since infancy (ages 2, 3Y/2, 5, and 5Y2 yr respectively), the mean height before initiating corrective therapy was -2.83±0.9 SD.
INDIVIDUALS
In each of the two infants diagnosed at less than 2 wk of age and who, as a consequence, were too young for stunting to have occurred, body weight was less than that at the time ofbirth by 11.1% in ID-4 at 8 days and by .2% in IV-15 at 10 days, an indication of failure to thrive. In each of the eight children and infants diagnosed after 1 mo of age, growth was impaired (mean height, -2.6±1.8 SD). In the two patients who were not stunted and who were documented to be nonacidotic at 2 mo and 6 mo of age (IV-13 and 111-1), growth velocity at time of diagnosis was abnormally reduced to 0.50 and 0.38, respectively, of the mean values predicted for age and sex, and height percentiles were less than halfthose obtaining at an earlier age: IV-13: 14th at 10 mo, 97.8th at 1 mo; III-1: 16th at 2 yr, 51st at 17 mo. In IV-13, the only patient in whom the possibility was investigated, an impaired renal acidification response to NH4Cl loading was demonstrated at 2 wk of age (Table I ). In the seven infants, including those who received alkali therapy in the neonatal period and in whom growth velocity had become subnormal (IV-15, age 10 mo,0.64 of the predicted mean; ID-4, age 3 mo, 0.43) (Fig. 2 B) , the mean linear growth velocity was 0.51+0.17 of the predicted mean at the time corrective alkali therapy was started.
In the three patients in whom alkali therapy was not initiated until childhood (IV-8, IV-10, and III-1 [ Fig. 4] ) and in two patients treated inadequately during childhood (ID-1 at age 5.5 yr and ID-4 at age 2.75 yr [ Fig. 3] ), growth velocity was 0.61+0.18 of the predicted mean in the period immediately before initiating corrective alkali therapy in childhood.
was in the 28.5th percentile (+28), significantly smaller than mean for the parent pairs reported by Tanner (0.02 < P < 0.05).
Tanner analysis. After therapy, the mean height of the eight patients whose ages permitted analysis by the Tanner technique was in the 69th percentile ±+7.7. The ages of only two children (111-1 and IV-10) permitted evaluation of growth by the Tanner technique both before and after therapy; the mean height of these was -3.35 SD before therapy and in the 53rd percentile after therapy.
To evaluate whether parental height significantly affected the height achieved by the patients, the height percentiles attained with therapy by each patient were compared, as analyzed by standard versus Tanner analysis; mean parental height significantly influenced the post-treatment height achieved by the patients (P = 0.02, Student's paired t test).
In each of the 10 infants and children with classic RTA in whom corrective alkali therapy was initiated at ages ranging from 10 days to 9.5 yr and maintained 1 -10 yr, normal stature was achieved and maintained (Figs. 1, 2A, 3A, and 4A). Almost immediately after alkali therapy was initiated, growth occurred at strikingly increased, supernormal rates (Figs. 2 B, 3 B, and 4 B) . (Fig. 1 A  andB) . The mean height of the 10 patients after sustained alkali therapy increased from the 1.4th to 37th percentile. The difference in the percentiles of the mean heights of the 10 patients before and after therapy was significant (0.02 <P < 0.01) (paired Student's t test). The mean height of the 10 patients after therapy was not significantly different from that of a normal population. The heights of the 10 patients after therapy were distributed from the 1st to the 99th percentile. The heights of four patients were in the 50th percentile or greater; the mean and median heights were almost the same at the 37th and 33rd percentiles, respectively. After alkali therapy, the height percentiles of the 10 patients were distributed normally when tested by either the Rank Normal Deviate Test (56, 57) (Fig. 1 B) or by the W. Statistic of Shapiro and Wilk (58) . The percentile for mean height of the unaffected parents (of the six patients with familial RTA) was 4.6 (±+-6.6), significantly smaller than the mean of a normal population. The mean height of all 10 pairs of parents The two infants treated in the neonatal period, IV-15 and ID-4, achieved statures of 57th and 16th percentile, respectively (Fig. 1 B) . The percentile of IV-15 was greater than that of her nonaffected parent (14th percentile); that of ID-4 was somewhat less than the 35th percentile predicted on the basis of midparental stature. When corrective alkali therapy was first administered, the two infants grew at rates greater than the mean predicted for their age (IV-15, 1.12; ID-4, 1.50) (Fig. 2 B) . The subsequent reduced growth rates of IV-15 and ID-4 were associated with sporadic parental noncompliance in administering alkali therapy (Fig. 2 B) . When corrective alkali therapy was reinstituted at ages 10 and 13 mo, respectively7, growth velocity increased immediately from subnormal to supernormal values (LV-15, twofold; ID-4, 2.8-fold) (Fig. 2 B) .
Four of the five infants in whom corrective alkali therapy was first administered after 1 mo of age were stunited at the time of diagnosis. All five infanits were of' normal stature within 4 mo of initiating alkali therapy, includinig ID-3, whose stature at age 4.5 mo was 5.5 SD below the predicted meani (Fig. 2 A) midparental height for normal children (54) , indicating that the stature of each patient is as large or larger than that which might be predicted for normal children with the same-sized parents. The percentiles of the present stature of the two patients with familial RTA (first treated as infants after 1 mo of age) relative to that of their nonaffected parent are 99:27 for IV-13 and 2: < 1 (-3.72 SD) for IV-11. For all seven infants, the rate of linear growth immediately after initiation of therapy was 1.62±+0.18 that ofthe mean predicted for sex and age (28) (Fig. 2 B) . This rate of growth, compared with that obtaining immediately before alkali therapy was initiated, 0.51±0.17, constitutes a 3.24-+0.94-fold increase.
CHILDREN
In patients IV-10 and III-1, a striking increase in growth rate occurred when alkali therapy was administered at ages 5 and 2 yr, respectively (Fig. 4 B) . Normal stature was achieved by IV-10 in 3 yr, height increasing to the 31st percentile from a value 3 SD below the predicted mean (Fig. 4A) . In 111-1, height percentile increased from the 16th to the 50th in 2 yr. In IV-8, in whom corrective alkali therapy was not initiated until the age of 9.5 yr, normal stature was achieved 1.5 yr thereafter. IV-8, whose height has been in the 1st percentile for the past 2 yr, can be considered to be of larger stature than his nonaffected father, whose height is -3.72 SD below the mean of adult males. The mean velocity of growth immediately after the initiation of adequate alkali therapy for IV-10, 111-1, and IV-8 (Fig.  4 B) , and for two patients diagnosed in infancy but inadequately treated during childhood, ID-1 and ID-4 ( Fig. 3 B) , increased to 1.50+0.29 that of the predicted mean velocity. This velocity, compared with that obtaining before corrective alkali therapy was administered, constituted a 2.31±0.94-fold increase.
The course of ID-1 is special: In both infancy and childhood, stature became normal after stunting when correction of acidosis was sustained with alkali therapy (Figs. 1 C, 2A, and 3A) . From the time stunting recurred shortly after infancy until the discovery was made 4.5 yr later that the alkali preparation dispensed as an outpatient was 0.1 the potency prescribed, this patient was repeatedly found to have metabolic acidosis (plasma bicarbonate 14-16 meq/liter). With reinstitution of continuously corrective alkali therapy at age 5.5 yr, growth velocity increased immediately to sustained, supernormal values (Fig. 3 B) , and normal height was achieved within 3 yr (Fig. 3A) .
Other possible determinants of growth before and after therapy Duration of acidosis (Fig. 1 C) . In the group of six patients first treated with alkali before 6 mo of age and in the group of five patients first treated after 6 mo (including ID-1 who received only one-tenth of the prescribed dose of alkali as an out-patient until age 51/2 yr), the height (SD) attained before therapy correlated significantly (inversely) with the maximal possible duration of prior acidosis.
After alkali therapy, the height percentiles attained correlated significantly (inversely) with the maximal possible duration of prior acidosis only in the group of patients in whom alkali therapy was initiated after 6 mo of age. In this group, two patients who were the offspring of the same set of parents attained greatly differing height percentiles after alkali therapy: IV-13, in whom alkali therapy was started at age 10 mo, attained the 99th percentile (Tanner); her brother, IV-10, in whom alkali therapy was not started until age 5 yr, attained the 38th percentile.
Inheritance of the RTA defect. Before alkali therapy, the mean height of the six patients with familial classic RTA was -1.94 (+0.92) SD, relative to the standard reference population; that of the four patients with the idiopathic defect, -2.97 (+2.07) SD. The two means are not significantly different.
After alkali therapy, the mean height attained by the six patients with familial RTA was in the 40th (+37.2) percentile, relative to the standard reference population; by the four patients with idiopathic RTA, in the 32.5th (±+31.1) percentile. When analyzed by the Tanner technique, the mean height attained by the five patients with familial RTA was in the 68th (±+24.9) percentile; by the three patients with idiopathic RTA in the 70th (+20) percentile. Whether analyzed by the standard or Tanner techniques, the mean height attained after alkali therapy by the patients with the familial defect was not significantly different statistically from that of the patients with idiopathic RTA.
Severity of acidosis. At the time alkali therapy was initiated, the patients' height percentiles did not correlate with the severity oftheir acidosis, as judged by the venous CO2 content.
Correction of acidosis, alkali requirement (Table II) In the 10 individuals ofthe present study, the greatest dosage ofalkali therapy required to sustain correction of acidosis ranged from 4.8 to 14.1 meq/kg per day. In all patients except IV-8, correction of acidosis required alkali therapy in an amount of at least 6 meq/kg per day during some period. In all children who were stunted, with the exception of IV-8, alkali therapy of at least this dosage was required before normal growth was achieved. In six of the patients, the corrective dosage of alkali therapy was less than 4 meq/kg per day in the initial observation period. In all but one child (ID-2), the corrective dosage of alkali therapy in the second The limits of the shaded and unshaded, enclosed areas indicate +1 and ±2.5 SD, respectively, of observation period was greater than that in the first; in six patients, the dosage in the second period was approximately twice that of the first. Subtle symptomatology usually accompanied partially corrected acidosis, whatever the dosage of alkali therapy; the children were usually pallid, they fatigued easily, and they were sometimes listless and anorexic. Plasma bicarbonate concentrations were 1-3 meq/ liter greater in the afternoon than in the morning, before the first dose of alkali therapy; in no case was frank alkalosis observed in the afternoon or evening. In no case was urinary excretion of bicarbonate substantially greater in the afternoon or evening than in the morning.
Bicarbonate excretion after prolonged alkali therapy (Table III) In each ofthe eight rapidly growing patients in whom correction of acidosis had been documented to be sustained for 1-6 mo on a fixed absolute amount of alkali, the corrective amount of alkali therapy ranged from 4.4 to 13.6 meq/kg per day. In these patients, Tanner (54) from data from normal children. The circle indicates the midpoint ofan observation period; the crossbars, the limits of the period. "Grids" for IV-8 and IV-10, from male populations; for III-1, from female.
patients, the urinary excretion of calcium was normal before alkali therapy was diminished. In the two patients whose dosage of alkali therapy was reduced to 3 meq/kg per day, urinary excretion of calcium became greater than 5 mg/kg per day, a value more than twice that of the upper limit recommended for adequate therapy (11, 37 (Table IV) Acidosis occurred as an outpatient in each of six rapidly growing children in whom the absolute dose of alkali prescribed as an outpatient had remained unchanged for 3-10 months. When initiated, the dose ranged from 4.4 to 12.0 meq/kg per day and was documented to be sufficient to maintain correction of acidosis. After periods of 3-10 mo, when acidosis had occurred, doses ranged from 4.3 to 10.3 meq/kg per day. In six patients studied under metabolic conditions in nine studies of [3] [4] [5] [6] [7] [8] [9] [10] days' duration, the values for serum venous CO2 content ranged from 17.0 to 23.3 meq/liter and arterial plasma HCO3-concentration from 17.0 to 21.9 meq/liter with continued administration of alkali at a dose of 4.3 to 10.3 meq/kg per day. Net base excretion ranged from 2.1 to 6.9 meq/kg per day with the exception of one study. (In this study, [IV-13, age 1 yr, 1/2 mo], urinary net base excretion was 0.4 meq/kg per day, and in distinction from all other studies, including the other two in IV-13, the patient had received alkali therapy for less than 1 yr [from only 10 to 121/2 mo of age] and the intake of NaCl was low-less than 2 meq/kg per day. In five of the six patients, net base excretion exceeded 3.4 meq/kg per day. Blood and plasma volumes, plasma renin activity, and urinary aldosterone excretion were within normal limits. There was no correlation between net base and urinary chloride excretion.
DISCUSSION
The results of the present studv indicate that in infants and children with classic RTA, impaired growth canl be prevented or corrected when alkali therapy is continuously provided in amounts that sustain correction of acidosis. In each of 10 infants and children with persisting classic RTA, continued provision of corrective alkali therapy was attended by achievement of persisting normal stature.
Before alkali therapy was initiated, the mean height of the 10 patients was in the 1.4th percentile. After sustained correction of acidosis with alkali therapy, the mean height was in the 37th percentile. After therapy, the heights of all the affected children were within the normal range and were distributed normally between the 1st through 99th percentiles when compared with a sex-and age-matched normal population; the heights of significantly different from the mean of the normal population, in contrast to the value ofthe mean height of the 10 sets of parents, which was significantly smaller than that of a normal population (0.02 < P < 0.05) (54) . In the group of eight patients whose height after therapy could be analyzed by the Tanner technique, the mean height was in the 69th percentile, taller than the mean predictable for age-and sex-matched normals. The Tanner technique has not been used in previously reported studies of growth in children with classic RTA.
Six of the patients, including four infants, were frankly stunted when alkali therapy was initiated. Prolonged acidosis preceded the occurrence of stunted growth in each of the four patients in whom the possibility could be investigated. Of the four patients who were not stunted when alkali therapy was initiated, two were two young (<2 wk of age) for stunting to have occurred. The two others were members of affected kindreds and had been observed initially to be nonacidotic; in both of these, however, height percentiles had decreased after the initial observations. After institution of alkali therapy, all 10 patients grew at velocities substantially greater than those predicted for their ages. Each of the eight patients in whom alkali therapy was begun after 1 mo of age grew at velocities greater than those obtaining immediately before alkali therapy was begun. In each of five infants in whom alkali therapy was initiated (at ages ranging from 1 mo to 1 yr), including one infant who was not frankly stunted, height velocity increased two-to fourfold within 2 mo of initiating therapy. All five infants attained normal stature within 6 mo of initiating therapy, including one whose height was 5.5 SD below the predicted mean when alkali therapy was begun at age 4.5 m11o. In each of three older stunted children, in whom corrective alkali therapy was initiated at ages 3.5, 5, and 5.5 yr, height velocity increased two-to threefold within 1 yr of initiating adequate alkali therapy and normal height stature was attained within 3 yr. A priori it could not have been predicted that in the present study each of the 10 children with classic RTA would attain normal height percentiles with alkali therapy. Given just one other published systematic study of growth in children with classic RTA, one might have inferred that growth was limited 1b pathogenetic factors other than those responsive to alkali therapy (30) . Since classic RTA canl be the expressioni of a with metabolic acidosis caused by RTA, physiological characterization of the disorder as classic (Type I) RTA has important prognostic power: with sustained correction of acidosis, normal height will be attained. If correcting alkali therapy is initiated before the age of 6 mo, the height attained will be limited only by the inherent and calculable genetic capacity for growth. Initiation of corrective alkali therapy after 6 mo of age may, to some undetermined extent, prevent full realization of the genetic potential for height attainment, but will not prevent attainment of normal height.
In patients with classic RTA of the present study, sustained correction of acidosis required administration of alkali therapy in amounts ranging from 5 to 14 meq/kg per day. This range of alkali dosage is substantially greater than that recently recommended for children with classic RTA, 1 to 3 meq/kg per day ( 11, 14, 19, 30, 36, 37) , but accords with that found necessary by many earlier investigators (2, (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) . In all but one patient, sustained correction of acidosis required alkali therapy at a dosage of at least 6 meq/kg per day during some period. In the five stunted patients in whom corrective alkali therapy was begun at 5.5 yr of age or younger, at least 6 meq/kg per day was required before normal height was achieved.
The magnitude of urinary bicarbonate wasting, 3.1-7.5 meq/kg per day, was the major determinant of the amount of alkali therapy in each of nine rapidly growing patients, studied when correction of acidosis required large doses of alkali therapy (4.8-13.6 meq/kg per day). In eight of the nine patients, the sum of the values of measured urinary net base excretion and an assumed endogenous acid production of 3 meq/kg per day equaled or exceeded the value ofdaily alkali intake; in the ninth patient, a rapidly growing 17Y2-mo-old girl, the magnitude ofurinary net base excretion (7.5 meq/kg per day) plus an endogenous production of nonvolatile acid of3 meq/kg per day accounted for 77% ofthe alkali requirement (13.6 meq/kg per day). In this patient, gut wasting ofbicarbonate and (or) an abnormally increased production of endogenous acid may have accounted for the remaining 3 meq/kg per day.
It might be argued that in these patients the large amounts of alkali therapy administered were more than those necessary to sustain correction of acidosis, and that excessive alkali therapy caused, or contributed to, the magnitude of bicarbonate wasting by overexpanding extracellular fluid volume (64, 65) . But (Table IV) . During acidosis, in each child the sum of the net base excretion and an assumed endogenous production of acid of 2-3 meq/kg per day closely approximated the amount of alkali administered. These findings provide strong evidence that in growing infants and children with classic RTA, large amounts of alkali therapy (>3 meq/kg per day) are required to sustain correction of acidosis because ofthe magnitude of renal bicarbonate wasting that predictably occurs in these patients.
The previously recommended dosage of alkali therapy of 1-3 meq/kg per day for infants and children with classic RTA has often been attended by a modest increase in stature but apparently never by the occurrence of normal stature after previous stunting (23-26, 30, 32) . Since this dosage of alkali has not been documented to sustain correction of acidosis in stunted infants and children with classic RTA, and since the 10 patients of the present study required alkali therapy in amounts ranging from 5 to 14 meq/kg per day to sustain correction of acidosis before normal stature was achieved, our findings suggest that an optimal growth response in patients with classic RTA may require alkali therapy in amounts sufficient to maintain plasma bicarbonate concentration within the normal range.
The possible causal relationship between acidosis and growth failure has been considered by a number of investigators (32, 35, (66) (67) (68) . In both children and adult patients with classic RTA, it has been repeatedly demonstrated that intestinal absorption of calcium is decreased during acidosis and increased with alkali therapy (1, 21, 25, 34, 69) . In children with classic RTA, impaired growth is frequently associated with frank rickets or osteopenia (1, 21, 23-25, 27, 70) . The bone disease of both children and adult patients with untreated classic RTA is predictably healed with alkali therapy alone (7, 23, 27) , and it would appear that the healing process can begin almost immediately after alkali therapy is initiated (70 Table I. 
